OPKO Health (OPK) 8-K Submission of Matters to a Vote of Security Holders

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2017

OPKO Health, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33528	75-2402409
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4400 Biscayne Blvd

Miami, Florida 33137

(Address of Principal Executive Offices) (Zip Code)

(305) 575-4100

Registrant’s telephone number, including area code

Not applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

ITEM 5.07.    Submission of Matters to a Vote of Security Holders.

On June 15, 2017, OPKO Health, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposal and corresponding vote.

1. All eight nominees were elected to the Board of Directors with each director receiving votes as follows:

Election of Directors	For		Withheld
Phillip Frost, M.D.		313,587,917		34,590,555
Jane H. Hsiao, Ph.D.		305,500,426		42,678,046
Steven D. Rubin		304,154,561		44,023,911
Richard M. Krasno, Ph.D.		344,682,759		3,495,713
Richard A. Lerner, M.D		286,997,023		61,181,449
John A. Paganelli		291,162,570		57,015,902
Richard C. Pfenniger, Jr.		333,531,789		14,646,683
Alice Lin-Tsing Yu, M.D., Ph.D.		296,686,376		18,792,096

2. The approval, on anon-binding advisory basis, of the compensation of the named executive officers of the Company (“Say On Pay”) as disclosed in the Company’s Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

For	Against	Abstain
316,825,919	30,329,801	1,022,752

3. The selection of one year, on anon-binding advisory basis, as the frequency with which the stockholders are provided anon-binding advisory vote on Say on Pay in future years. The votes on this proposal were as follows:

1 Year	2 Years	3 Years	Abstain
309,086,990	692,622	37,254,593	1,144,267

Based on this result and in accordance with the previous recommendation of the Company’s Board of Directors, the Company will hold anon-binding, advisory vote on Say On Pay every year.

There were no brokernon-votes for the proposals. No other matters were considered or voted upon at the meeting.

ITEM 7.01.    Regulation FD Disclosure.

On June 15, 2017, the Company held its Annual Meeting of Stockholders. Copies of the presentations presented at the Annual Meeting are furnished with this Current Report on Form8-K as Exhibit 99.1.

Statements are made in the presentations which are not historical are forward-looking statements that reflect management’s current views with respect to future events and performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Such statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

The information contained in Item 7.01 to this Current Report on Form8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act, unless expressly stated otherwise.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	OPKO Presentation – 2017 Annual Meeting of Stockholders held June 15, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OPKO Health, Inc.
Date: June 15, 2017	By	/s/ Adam Logal
	Name:	Adam Logal
	Title:	Senior. Vice President,
		Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	OPKO Presentation – 2017 Annual Meeting of Stockholders held June 15, 2017.